Please disable your Ad Blocker to better interact with this website.

New Info On Paxlovid Confirms January 2022 3-Part Series Warning

Written by:

Published on: May 2, 2022

If you recall in January of this year, Sons of Liberty Media carried a three-part series on Pfizer’s oral drug to combat covid-19 called Paxlovid (see here, here, and here), which received emergency use authorization (EUA) in December 2021. Warnings were issued on the drug-drug interactions, the adverse events associated with the drug ritonavir (Norvir) contained in the Paxlovid regime (many not disclosed to patients or health care providers), and the limited clinical trial data especially for those under the age of 18. Readers were urged to exercise caution and to beware of this “treatment” for a non-proven to exist “virus”.

As it turns out, the warnings against Paxlovid were spot on. On April 29, 2022, Pfizer announced a recent, large-scale, late-stage clinical trial found Paxlovid failed to prevent symptomatic infection of “people living with a person who has the disease”. This is confirmed via the announcement of the conclusion of the trials on the Pfizer website. The story was also carried at The Epoch Times.

Pfizer announced Friday that a recent large, late-stage trial found that its COVID-19 antiviral pill, Paxlovid, failed at preventing symptomatic infection of people living with a person who has the disease.

The trial enrolled 2,957 participants aged 18 and older who live in the same household as another person who has COVID-19 with symptoms. They were given either Paxlovid or a placebo twice daily for five or 10 days.

Researchers reported that those who took Paxlovid for 5 days were 32 percent less likely to become infected compared to the placebo group. People who took Paxlovid for 10 days were 37 percent less likely to get infected. The results were not statistically significant, however, which means it could possibly be due to chance.

These results … were not statistically significant and, as such, the primary endpoint of reducing the risk of confirmed and symptomatic COVID-19 infection in adults who had been exposed to the virus through a household contact was not met,” the company said in a release.

While we are disappointed in the outcome of this particular study, these results do not impact the strong efficacy and safety data we’ve observed in our earlier trial for the treatment of COVID-19 patients at high risk of developing severe illness,” Pfizer Chief Executive Albert Bourla said in a statement.

As has been observed with Pfizer and other pharmaceutical companies producing “interventions” for covid-19, the efficacy and safety data has been compromised or out and out falsified to gain emergency use authorization and approval from the Food and Drug Administration (FDA) for products that have been observed and proven to be ineffective and unsafe.

If you recall, Paxlovid is a combination of two drugs: ritonavir (Norvir), a recycled HIV drug, and nirmatrelvir, a new SARS-CoV-2 protease inhibitor drug invented by Pfizer. The development of this drug followed a “warp speed” track skipping crucial steps throughout the process, including authorization. Yet, this drug has been utilized in 60 countries thus far for covid-19.

The Epoch Times continued:

According to the U.S. Food and Drug Administration (FDA), ritonavir “may cause liver damage” and so “caution should be exercised when giving Paxlovid to patients with preexisting liver diseases, liver enzyme abnormalities or liver inflammation.”

The FDA also said that using Paxlovid in people with uncontrolled or undiagnosed HIV-1 infection “may lead to HIV-1 drug resistance.”

Pfizer’s announcement comes as researchers at the National Institute of Allergy and Infectious Diseases (NIAID) are planning to investigate how and why some people who have taken a five-day course of Paxlovid experience a repeat of COVID-19, reported Bloomberg.

Clifford Lane, deputy director for clinical research at NIAID, told the outlet that the issue is “a pretty urgent thing for us to get a handle on.” He said the agency is discussing with scientists at the Centers for Disease Control and Prevention (CDC) about carrying out a number of possible epidemiological and clinical studies to learn about these rebound cases.

Researchers at the VA Boston Healthcare System earlier this week published a preprint (pdf) about a case study of a 71-year-old man who quickly recovered from COVID-19 after taking Paxlovid, only to have a relapse of symptoms and an increase in viral levels just nine days after his first COVID-19 positive test. The symptoms and viral levels resolved days later. The COVID-19 rebound case related to Paxlovid is the first to be documented in medical literature.

Paul Sax, a Harvard Medical School professor and the clinical director of the Division of Infectious Diseases at Brigham and Women’s Hospital, told Bloomberg that if people have symptoms that worsen after taking Paxlovid, “it’s probably still COVID.”

Sax on April 25 had reported about a rebound of COVID-19 in one of his HIV patients after the person took Paxlovid.

In the third article of the three-part series on Paxlovid at Sons of Liberty Media, the full text of the Physicians’ Desk Reference for ritonavir was linked showing an extensive contraindications with many commonly prescribed and over-the-counter medications, along with warnings issued by an article from The Lancet. This information was available less than three weeks after the FDA issued an EUA for Paxlovid. Much of this information came from the in-depth examination of ritonavir (Norvir) since nirmatrelvir was so new, little was known about it.

Now, a little over four months after the EUA, what was warned about Paxlovid has now come to be laid bare for all to see. There is much more risk than benefit in Paxlovid, as was said approximately two weeks after the FDA’s EUA. The question that continues to burn in the mind is, “why are the majority of physicians and health care professionals ignorant of this information readily available in January of 2022 that only took a bit of research to find?” How much more evidence of scientific and medical fraud need to be laid before the public in order to break the mind control manipulation of the government, the media, and international agents? The answer is simple – there are some that are so far gone regarding mind control and brainwashing there is no amount of evidence that can be provided to help them. Unfortunately, many see it within their own families.

This entire covid-19 debacle is far from over. The players involved in perpetrating this fraud have received too much secondary gain to stop now. Moreover, the “plan” is being executed in phases that incorporates “lulls” in countermeasure implementation and includes devastation in areas affecting the everyday lives of the public. Between destruction of the medical system as we have known it (personal physician care), the destruction of the food supply chain, and current intentional collapse of society, people are already suffering – this is just the beginning.

Become an insider!

Sign up to get breaking alerts from Sons of Liberty Media.

Don't forget to like SonsOfLibertyMedia.com on Facebook and Twitter.
The opinions expressed in each article are the opinions of the author alone and do not necessarily reflect those of SonsOfLibertyMedia.com.

Trending on The Sons of Liberty Media

Newsletter SignupStay up to date on the latest news: Sign up for the Sons of Liberty newsletter!

Stay up to date on the latest news: Sign up for the Sons of Liberty newsletter!